专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

91. 发明授权

EP1495035B1 VERFAHREN ZUR HERSTELLUNG VON BIS(PERFLUORALKYL)PHOSPHINSÄUREN UND DEREN SALZE 有权
标题翻译：用于生产BIS（全氟烷基）次膦及其盐的
公开(公告)号：EP1495035B1
公开(公告)日：2010-06-30
申请号：EP03712030.0
申请日：2003-03-17
申请人： Merck Patent GmbH
发明人： WELZ-BIERMANN, Urs , IGNATYEV, Nikolai , WEIDEN, Michael , HEIDER, Udo , KUCHERYNA, Andriy , WILLNER, Helge , SARTORI, Peter
IPC分类号： B01F17/00 , B01J31/02 , C07C211/63 , C07D231/12 , C07D233/54 , C07D233/56 , C07D249/08 , C07F9/30 , C07F9/54
CPC分类号： B01F17/0064 , B01J31/0231 , B01J31/0284 , B01J31/0288 , B01J31/0289 , B01J31/0291 , B01J2531/98 , C07C211/63 , C07D231/12 , C07D233/54 , C07D233/56 , C07D249/08 , C07F9/301 , C07F9/5456
摘要： The invention relates to a method for producing bis(perfluoroalkyl)phosphinic acids, according to which at least one difluorotris(perfluoroalkyl)phosphorane or at least one trifluorobis(perfluoroalkyl)phosphorane is reacted with hydrogen fluoride in a suitable reaction medium and the obtained reaction mixture is heated. The invention also relates to salts of the bis(perfluoroalkyl)phosphinic acids and the use thereof.

92. 发明公开

EP2085391A2 Inhibitors of factor XA and other serine proteases involved in the coagulation cascade 审中-公开
标题翻译： Germerungskaskade独立者Serin-Proteasen的Hemmer des Faktors XA und anderer
公开(公告)号：EP2085391A2
公开(公告)日：2009-08-05
申请号：EP08101927.5
申请日：2002-11-14
申请人： Warner-Lambert Company LLC
发明人： Bigge, Christopher, Francklin , Dudley, Danette, Andrea , Edmunds, Jeremy, John , Van Huis, Chad, Alan , Casimiro-Garcia, Agustin , Filipski, Kevin, James , Kohrt, Jeffrey, Thomas
IPC分类号： C07D231/12 , C07D233/56 , C07D249/08 , C07D213/64 , C07D211/76 , C07D401/04 , C07D237/14
CPC分类号： C07D231/12 , C07D207/16 , C07D207/20 , C07D207/22 , C07D207/24 , C07D207/26 , C07D207/27 , C07D211/76 , C07D213/64 , C07D231/06 , C07D233/56 , C07D237/14 , C07D249/08 , C07D401/04 , C07D401/12 , C07D401/14 , C07D403/12 , C07D413/12
摘要： The invention relates to a process for preparing a compound of Formula I:

or a pharmaceutically acceptable salt thereof wherein A, B, C, W 1 and G are as defined in the present application.
摘要翻译：本发明涉及制备式I化合物或其药学上可接受的盐的方法，其中A，B，C，W 1和G如本申请中所定义。

93. 发明公开

EP2064951A1 Use of a substituted imidazole, derivatives or salts thereof for the preparation of a medicament for the treatment of a cell proliferative disorder 审中-公开
标题翻译：使用的取代的咪唑衍生物或其盐用于制备药物的制造中用于治疗细胞增殖性疾病
公开(公告)号：EP2064951A1
公开(公告)日：2009-06-03
申请号：EP09004137.7
申请日：2000-10-06
申请人： Taiji Biomedical, Inc.
发明人： Newman, Michael James , Dixon, William Ross
IPC分类号： A01N43/50 , A61K31/415 , C07D233/54 , C07D233/56 , C07D233/58
CPC分类号： C07D233/64 , A61K31/415 , A61K45/06 , A61K2300/00
摘要： The present invention relates to the use of a compound having the formula I, a derivative or a salt thereof for the preparation of a medicament for the treatment of a cell proliferative disorder, wherein the cell proliferative disorder is further treated by a chemotherapeutic agent
摘要翻译：本发明涉及使用化合物具有通式I，其衍生物或用于细胞增殖性病症的治疗的药物的制备中它们的盐，worin细胞增殖病症是化疗剂此外，通过治疗

94. 发明公开

EP1828141A1 A ONE-POT PROCESS FOR THE PREPARATION OF ANTIEMETIC AGENT, 1,2,3,9-TETRAHYDRO-9-METHYL-3[(2-METHYL)-1H-IMIDAZOLE-1-YL)METHYL]-4H-CARBAZOL-4-O 审中-公开
标题翻译：制备一锅法的止吐剂-1,2,3,9-四氢-9-甲基-3 - [（2-甲基）-1H-咪唑-1-基）甲基] -4H-咔唑-4-酮
公开(公告)号：EP1828141A1
公开(公告)日：2007-09-05
申请号：EP04821388.8
申请日：2004-10-26
申请人： IPCA Laboratories Limited
发明人： KUMAR, Ashok, 4/203-4, Sterling CHS , SINGH, Dharmendra, Building No.D/3 A Wing , JADHAV, Atul, 8. J. M. Pereira Chawl , PANDYA, Darpan N., A-502, Shantidoot co-op Hsg. So , PANMAND, Deepak S., A-502, Shantidoot co-op Hsg.So , THAKUR, Gajendrasingh R, Gaurav Gunjan Ltd
IPC分类号： C07D233/56 , C07D403/06 , A61K31/415
CPC分类号： C07D403/06
摘要： A one-pot industrial process for preparing 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazole-1-yl)methyl]-4H-carbazol-4-one of Formula-(I) from 1,2,3,9-tetrahydro-9-methyl-4H-carbazol-4-one of Formula-(IV) involves reaction of Formula (IV) with HNR1R2 salt and paraformaldehyde, where R1,R2 are independently alkyl groups or together forms a cyclic alkyl group, in a solvent system of acetic acid and hydrocarbon solvent to form a crude mixture of intermediate compounds of Formula (III) and (VIII), which is converted to ondansetron (Formula (I)) without isolation by reaction with 2methyimidazole in a suitable solvent system in the same pot.

95. 发明公开

EP1718342A1 TECHNETIUM-AND RHENIUM-BIS(HETEROARYL) COMPLEXES, AND METHODS OF USE THEREOF 审中-公开
标题翻译：锝和铼BIS（杂芳基）配合物及使用方法
公开(公告)号：EP1718342A1
公开(公告)日：2006-11-08
申请号：EP05722979.1
申请日：2005-02-14
申请人： Molecular Insight Pharmaceuticals, Inc.
发明人： BABICH, John , ECKELMAN, William, C. , MARESCA, Kevin, P. , VALLIANT, John, W. , ZUBIETA, Jon
IPC分类号： A61K51/00 , C07F5/00 , C07D233/56
CPC分类号： C07D233/64 , A61K51/04 , C07D213/38 , C07D217/14 , C07D235/14 , C07D235/20 , C07D277/28 , C07F13/005
摘要： One aspect of the invention relates to complexes of technetium (Tc) and rhenium (Re) with various heteroaromatic ligands, e.g., quinolinyl and isoquinolinyl ligands, and their use in fluoresence and radioimaging for a variety of clinical diagnostic applications, as well as radiopharmaceuticals for therapeutic applications. Another aspect of the invention relates to quinolinyl and isoquinolinyl ligands that form a portion of the aforementioned complexes. Methods for the preparation of the technetium and rhenium complexes are also described. Another aspect of the invention relates to quinolinyl and isoquinolinyl ligands based on derivatized lysine, alanine and bis-amino acids for conjugation to small peptides by solid phase synthetic methods. Additionally, the invention relates to methods for imaging regions of a mammal using the complexes of the invention.

96. 发明公开

EP1615866A1 INDENE DERIVATIVES AS PHARMACEUTICAL AGENTS 有权
标题翻译： INDEN DERIVATE ALS PHARMAZEUTIKA
公开(公告)号：EP1615866A1
公开(公告)日：2006-01-18
申请号：EP04727484.0
申请日：2004-04-15
申请人： Inflazyme Pharmaceuticals, Ltd.
发明人： RAYMOND, Jeffery, R. , HAN, Kang , ZHOU, Yuanlin , HE, Yuehua , NOREN, Bradley , YEE, James, Gee, Ken
IPC分类号： C07C35/21 , C07C35/32 , C07C35/52 , C07C69/03 , C07C215/42 , C07C233/18 , C07C279/08 , C07C311/04 , C07D213/30 , C07D233/56 , A61K31/047 , A61K31/133 , A61K31/155 , A61K31/164 , A61K31/18
CPC分类号： C07C35/32 , C07C35/14 , C07C35/21 , C07C51/083 , C07C51/347 , C07C62/34 , C07C69/013 , C07C213/00 , C07C213/08 , C07C215/42 , C07C233/18 , C07C233/21 , C07C233/72 , C07C247/14 , C07C279/08 , C07C311/04 , C07C315/00 , C07C2601/14 , C07C2602/08 , C07C2602/24 , C07D207/335 , C07D211/58 , C07D213/30 , C07D213/38 , C07D213/74 , C07D233/54 , C07D233/64 , C07D295/096 , C07D307/66 , C07D317/66 , C07D317/70 , Y10S514/825 , Y10S514/826 , Y10S514/863
摘要： Compounds of formula (Ia): wherein R1, R2, R3, R4a, R4b, R5 and R6 are defined herein, as well as other indene derivatives are disclosed herein. Pharmaceutical compositions containing the compounds and methods of using the compounds are also disclosed.
摘要翻译：式（Ia）化合物：其中R1，R2，R3，R4a，R4b，R5和R6如本文所定义，以及其它茚衍生物在本文中公开。还公开了含有化合物的药物组合物和使用该化合物的方法。

97. 发明授权

EP0957917B1 VITRONECTIN RECEPTOR ANTAGONISTS 失效
标题翻译：连素受体拮抗剂
公开(公告)号：EP0957917B1
公开(公告)日：2005-12-07
申请号：EP97909979.3
申请日：1997-10-01
申请人： SMITHKLINE BEECHAM CORPORATION
发明人： CALLAHAN, James, Francis , COUSINS, Russell, Donovan , KEENAN, Richard, McCullock , KWON, Chet , MILLER, William, Henry , UZINKAS, Irene, Nijole
IPC分类号： C07D401/12 , C07D403/12 , C07D417/12 , C07D471/04 , A61K31/44 , A61K31/47 , A61K31/52 , A61K31/55 , A61K31/415 , A61K31/445 , A61K31/495 , C07D223/16 , C07D233/56 , C07D233/64 , C07D235/18 , C07D235/22 , C07D243/14
CPC分类号： C07D223/16 , A61K31/55 , A61K33/24 , A61K45/06 , C07D401/12 , C07D403/12 , C07D417/12 , Y02P20/55 , Y02P20/582 , A61K31/47 , A61K2300/00
摘要： Benzodiazepine compounds (I) of formula (I'; R = H), and their salts, are new: R1 = 1-4C alkyl, 2-4C alkenyl, 2-4C alkynyl, 3-4C oxoalkenyl, 3-4C oxoalkynyl, 1-4C aminoalkyl, 3-4C aminoalkenyl, 3-4C aminoalkynyl, (all optionally substituted by one A and one or more R10 or R7), H or R7; A = 3-6C cycloalkyl, Het or Ar; R7 = COR8, COC(R')2R9, C(S)R8, S(O)mOR', S(O)mNR'R'', PO(OR'), PO(OR')2, NO2 or tetrazolyl; R8 = OR', NR'R'', NR'SO2R', NR'OR' or OC(R')2COOR'; R9 = OR', CN, S(O)rR', S(O)mN(R')2, COR', CON(R')2 or COOR'; R10 = 1-6C alkyl, 1-6C oxoalkyl, 2-6C alkenyl, 2-6C alkynyl, 1-6C alkyloxy, 1-6C alkylamino, S(O)r-(1-6C alkyl) (all optionally substituted by A), H, OH, NH2, S(O)rH, OR11, CN, NR'R11, NO2, CF3, S(O)rCF3, COOR' or CON(R')2; R11 = R', COR', CON(R')2, COOR', S(O)mR' or S(O)mN(R')2; R2 = a group of formula (a)-(i); W = (CHRg)a-U-(CHRg)b; U = bond, CO, C(Rg)2, C(=CRg2), S(O)k, O, NRg, CRgORg, CRg(ORk)C(Rg)2, C(Rg)2CRg(ORk), COC(Rg)2, C(Rg)2C(O), CONRi, NRiCO, OC(O), C(O)O, C(S)O, OC(S), C(S)NRg, NRgC(S), S(O)2NRg, NRgS(O)2, N=N, NRgNRg, NRgC(Rg)2, C(Rg)2NRg, C(Rg)2O, OC(Rg)2, CC or CRg=CRg; G = NRe, S or O; Rg = H, 1-6C alkyl (optionally substituted by Het, 3-7C cycloalkyl or Ar) or Het, 3-7C cycloalkyl or Ar; Rk = Rg, CORg or COORf; Ri = Rg or 1-6C alkyl (substituted by 1-3 halo, CN, N(Rg)2, ORg, SRg, COORg or CON(Rg)2); Rf = H, Ar, or 1-6C alkyl (optionally substituted by Ar); Re = Rg or (CH2)kCOORg; Rb, Rc = H, A, 1-6C alkyl (optionally substituted by A), halo, CF3, ORf, S(O)kRf, CORf, NO2, N(Rf)2, CON(Rf)2 or CH2N(Rf)2; or Rb+Rc complete a 5-6 membered aromatic or non-aromatic carbocyclic or heterocyclic ring (optionally mono- to tri- substituted by halo, CF3, 1-4C alkyl, ORf, S(O)kRf, CORf, COORf, OH, NO2, N(Rf)2, CON(Rf)2, CH2N(Rf)2 or methylenedioxy; Q = C-Ry, and one Q may also be N; R' = H, Ar, 3-6C cycloalkyl or 1-6C alkyl (optionally substituted by Ar or (3-6C cycloalkyl); R'' = R', COR' or COOR'; Ry = H, halo, ORg, SRg, CN, NRgRk, NO2, CF3, S(O)rCF3, COORg, CORg, CON(Rg)2 or 1-6C alkyl (optionally substituted by halo, ORg, SRg, CN, NRgR'', NO2, CF3, S(O)rR', COORg, CORg or CON(Rg)2); a, b, k, r, s = 0-2; m = 1 or 2; u, v = 0 or 1. Also defined is a variable R''' = H, A, 1-6C alkyl (optionally substituted by A), halo, CF3, ORf, S(O)kRf, CORf, NO2, N(Rf)2, CON(Rf)2 or CH2N(Rf)2 which is not shown in the formula. Also claimed is a composition comprising (I), a carrier, and optionally an antineoplastic agent or inhibitor of bone resorption. Intermediates (II) of formula (I'; R = 1-6C alkyl).

99. 发明公开

EP1419770A4 APO AI EXPRESSION ACCELERATING AGENT 审中-公开
标题翻译：代理加速表达APO AI作者：
公开(公告)号：EP1419770A4
公开(公告)日：2005-08-03
申请号：EP01958448
申请日：2001-08-24
申请人： SHIONOGI & CO
发明人： ISHIZUKA NATSUKI , NAGATA KIYOSHI , YAMAMORI TERUO , SAKAI KATSUNORI
IPC分类号： C07D249/06 , A61K31/341 , A61K31/351 , A61K31/381 , A61K31/40 , A61K31/4025 , A61K31/41 , A61K31/415 , A61K31/4155 , A61K31/4164 , A61K31/4178 , A61K31/4192 , A61K31/42 , A61K31/421 , A61K31/422 , A61K31/4245 , A61K31/425 , A61K31/426 , A61K31/427 , A61K31/433 , A61K31/4427 , A61K31/443 , A61K31/4433 , A61K31/4436 , A61K31/4439 , A61K31/454 , A61K31/496 , A61K31/501 , A61K31/506 , A61K31/5375 , A61K31/5377 , A61P3/06 , A61P9/10 , A61P43/00 , C07D207/32 , C07D207/34 , C07D207/50 , C07D231/12 , C07D231/14 , C07D233/56 , C07D249/08 , C07D249/10 , C07D249/12 , C07D257/04 , C07D261/08 , C07D263/32 , C07D271/06 , C07D271/10 , C07D271/107 , C07D277/22 , C07D277/24 , C07D285/06 , C07D285/08 , C07D285/10 , C07D285/12 , C07D285/135 , C07D307/36 , C07D307/38 , C07D307/42 , C07D307/68 , C07D333/06 , C07D333/12 , C07D333/16 , C07D333/18 , C07D401/04 , C07D401/14 , C07D403/04 , C07D405/04 , C07D405/14 , C07D407/04 , C07D409/04 , C07D409/14 , C07D413/04 , C07D413/06 , C07D413/14 , C07D417/04 , C07D417/10 , C07D417/14
CPC分类号： C07D231/12 , A61K31/351 , A61K31/381 , A61K31/40 , A61K31/4025 , A61K31/41 , A61K31/415 , A61K31/4164 , A61K31/4178 , A61K31/42 , A61K31/421 , A61K31/422 , A61K31/425 , A61K31/426 , A61K31/427 , A61K31/433 , A61K31/4436 , A61K31/4439 , A61K31/454 , A61K31/501 , A61K31/506 , A61K31/5377 , C07D271/06 , C07D271/107 , C07D277/24 , C07D405/04 , C07D413/04 , C07D413/06 , C07D417/04
摘要： A medicinal composition having apo AI expression accelerating action, which comprises a compound represented by the formula (I): (I) wherein Y1 represents O, S or NR1, Y2, Y3, Y4 and Y5 represent CR2 or N, CR3 or N, CR4 or N, and CR5 or N, respectively, R1 represents A1, -Z-A2, hydrogen, a lower alkyl or the like, R2, R3, R4 and R5 represent A1, -Z-A2, hydrogen, a halogen or the like, -Z- represents a single bond, -CR6=CR7- or the like, R6 and R7 are hydrogen or a lower alkyl, and A1 and A2 are an aryl, a heterocyclic group or the like, or the like.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式